These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

147 related articles for article (PubMed ID: 36353052)

  • 1. Tacrolimus Monotherapy is Safe in Immunologically Low-Risk Kidney Transplant Recipients: A Randomized-Controlled Pilot Study.
    de Weerd AE; Fatly ZA; Boer-Verschragen M; Kal-van Gestel JA; Roelen DL; Dieterich M; Betjes MGH
    Transpl Int; 2022; 35():10839. PubMed ID: 36353052
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Mycophenolate mofetil hampers antibody responses to a broad range of vaccinations in kidney transplant recipients: Results from a randomized controlled study.
    Fatly ZA; Betjes MGH; Dik WA; Fouchier RAM; Reinders MEJ; de Weerd AE
    J Infect; 2024 Mar; 88(3):106133. PubMed ID: 38432583
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A randomized trial with steroids and antithymocyte globulins comparing cyclosporine/azathioprine versus tacrolimus/mycophenolate mofetil (CATM2) in renal transplantation.
    Vacher-Coponat H; Moal V; Indreies M; Purgus R; Loundou A; Burtey S; Brunet P; Moussi-Frances J; Daniel L; Dussol B; Berland Y
    Transplantation; 2012 Feb; 93(4):437-43. PubMed ID: 22228415
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Long-term renal transplant function in recipient of simultaneous kidney and pancreas transplant maintained with two prednisone-free maintenance immunosuppressive combinations: tacrolimus/mycophenolate mofetil versus tacrolimus/sirolimus.
    Gallon LG; Winoto J; Chhabra D; Parker MA; Leventhal JR; Kaufman DB
    Transplantation; 2007 May; 83(10):1324-9. PubMed ID: 17519781
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Tacrolimus in pancreas transplantation: a multicenter analysis. Tacrolimus Pancreas Transplant Study Group.
    Gruessner RW
    Clin Transplant; 1997 Aug; 11(4):299-312. PubMed ID: 9267719
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Is simplification of immunosuppressive medication a way to promote medication adherence of kidney transplant recipients? Findings from a randomized controlled trial.
    van Zanten R; de Weerd A; Betjes M; Boer-Verschragen M; Massey EK
    Transpl Int; 2021 Sep; 34(9):1703-1711. PubMed ID: 34448273
    [TBL] [Abstract][Full Text] [Related]  

  • 7. De novo low-dose sirolimus versus mycophenolate mofetil in combination with extended-release tacrolimus in kidney transplant recipients: a multicentre, open-label, randomized, controlled, non-inferiority trial.
    Huh KH; Lee JG; Ha J; Oh CK; Ju MK; Kim CD; Cho HR; Jung CW; Lim BJ; Kim YS;
    Nephrol Dial Transplant; 2017 Aug; 32(8):1415-1424. PubMed ID: 28810721
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Conversion from tacrolimus-mycophenolate mofetil to tacrolimus-mTOR immunosuppression after kidney-pancreas transplantation reduces the incidence of both BK and CMV viremia.
    Knight RJ; Graviss EA; Nguyen DT; Kuten SA; Patel SJ; Gaber L; Gaber AO
    Clin Transplant; 2018 Jun; 32(6):e13265. PubMed ID: 29676018
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Randomized trial of 3 maintenance regimens (TAC/SRL vs. TAC/MMF vs. CSA/SRL) with low-dose corticosteroids in primary kidney transplantation: 18-year results.
    Ciancio G; Gaynor JJ; Guerra G; Roth D; Chen L; Kupin W; Mattiazzi A; Ortigosa-Goggins M; Moni L; Burke GW
    Clin Transplant; 2020 Dec; 34(12):e14123. PubMed ID: 33070366
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Freedom from rejection and stable kidney function are excellent criteria for steroid withdrawal in tacrolimus-treated kidney transplant recipients.
    Włodarczyk Z; Wałaszewski J; Perner F; Vitko S; Ostrowski M; Bachleda P; Kokot F; Klinger M; Szenohradsky P; Studenik P; Navratil P; Asztalos L; Rutkowski B; Nagy KK; Hickey D
    Ann Transplant; 2002; 7(3):28-31. PubMed ID: 12465429
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Graft survival following living-donor renal transplantation: a comparison of tacrolimus and cyclosporine microemulsion with mycophenolate mofetil and steroids.
    Bunnapradist S; Daswani A; Takemoto SK
    Transplantation; 2003 Jul; 76(1):10-5. PubMed ID: 12865780
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparison of four different immunosuppression protocols without long-term steroid therapy in kidney recipients monitored by surveillance biopsy: five-year outcomes.
    Anil Kumar MS; Irfan Saeed M; Ranganna K; Malat G; Sustento-Reodica N; Kumar AM; Meyers WC
    Transpl Immunol; 2008 Nov; 20(1-2):32-42. PubMed ID: 18773960
    [TBL] [Abstract][Full Text] [Related]  

  • 13. An open-label, randomized trial indicates that everolimus with tacrolimus or cyclosporine is comparable to standard immunosuppression in de novo kidney transplant patients.
    Sommerer C; Suwelack B; Dragun D; Schenker P; Hauser IA; Witzke O; Hugo C; Kamar N; Merville P; Junge M; Thaiss F; Nashan B;
    Kidney Int; 2019 Jul; 96(1):231-244. PubMed ID: 31027892
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Influence of tacrolimus plus mycophenolate mofetil regimens on acute rejection rate and diabetes mellitus development in renal transplant recipients.
    Demirbaş A; Tuncer M; Yavuz A; Gürkan A; Kaçar S; Cetinkaya R; Tekin S; Akbaş SH; Akaydin M; Ersoy F; Yakupoğlu G
    Transplant Proc; 2004; 36(1):175-7. PubMed ID: 15013338
    [TBL] [Abstract][Full Text] [Related]  

  • 15. New strategies using 'low-dose' mycophenolate mofetil to reduce acute rejection in patients following kidney transplantation.
    Ulsh PJ; Yang HC; Holman MJ; Ahsan N
    J Transpl Coord; 1999 Jun; 9(2):114-8. PubMed ID: 10703393
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy and Safety of Everolimus Plus Low-Dose Tacrolimus Versus Mycophenolate Mofetil Plus Standard-Dose Tacrolimus in De Novo Renal Transplant Recipients: 12-Month Data.
    Qazi Y; Shaffer D; Kaplan B; Kim DY; Luan FL; Peddi VR; Shihab F; Tomlanovich S; Yilmaz S; McCague K; Patel D; Mulgaonkar S
    Am J Transplant; 2017 May; 17(5):1358-1369. PubMed ID: 27775865
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Impact of tacrolimus-sirolimus maintenance immunosuppression on proteinuria and kidney function in pancreas transplant alone recipients.
    Kandula P; Fridell J; Taber TE; Sharfuddin A; Yaqub MS; Phillips CL; Chen J; Mujtaba M
    Transplantation; 2012 Nov; 94(9):940-6. PubMed ID: 23037007
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Safety and efficacy of tacrolimus in combination with mycophenolate mofetil (MMF) in cadaveric renal transplant recipients. FK506/MMF Dose-Ranging Kidney Transplant Study Group.
    Miller J; Mendez R; Pirsch JD; Jensik SC
    Transplantation; 2000 Mar; 69(5):875-80. PubMed ID: 10755543
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Tacrolimus-based, steroid-free regimens in renal transplantation: 3-year follow-up of the ATLAS trial.
    Krämer BK; Klinger M; Vítko Š; Glyda M; Midtvedt K; Stefoni S; Citterio F; Pietruck F; Squifflet JP; Segoloni G; Krüger B; Sperschneider H; Banas B; Bäckman L; Weber M; Carmellini M; Perner F; Claesson K; Marcinkowski W; Ostrowski M; Senatorski G; Nordström J; Salmela K
    Transplantation; 2012 Sep; 94(5):492-8. PubMed ID: 22858806
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A prospective randomized trial of tacrolimus and prednisone versus tacrolimus, prednisone and mycophenolate mofetil in primary adult liver transplantation: a single center report.
    Jain A; Kashyap R; Dodson F; Kramer D; Hamad I; Khan A; Eghestad B; Starzl TE; Fung JJ
    Transplantation; 2001 Sep; 72(6):1091-7. PubMed ID: 11579306
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.